Association for Molecular Pathology v. Myriad Genetics, Inc.
GPTKB entity
Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:United_States_Supreme_Court_case
|
| gptkbp:alsoKnownAs |
gptkb:Myriad_Genetics_case
|
| gptkbp:arguedDate |
April 15, 2013
|
| gptkbp:citation |
gptkb:569_U.S._576
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:date |
June 13, 2013
|
| gptkbp:decision |
unanimous decision
|
| gptkbp:docketNumber |
12-398
|
| gptkbp:heldBy |
Naturally occurring DNA sequences cannot be patented
cDNA is patent eligible because it is not naturally occurring |
| gptkbp:judge |
gptkb:Supreme_Court_of_the_United_States
|
| gptkbp:opinionBy |
gptkb:Justice_Clarence_Thomas
|
| gptkbp:petitioner |
gptkb:Association_for_Molecular_Pathology
|
| gptkbp:predecessor |
gene patenting cases
|
| gptkbp:relatedTo |
gptkb:BRCA1_gene
gptkb:BRCA2_gene |
| gptkbp:response |
gptkb:Myriad_Genetics,_Inc.
|
| gptkbp:subject |
gptkb:US_patent
gptkb:biotechnology genetics |
| gptkbp:bfsParent |
gptkb:Diamond_v._Chakrabarty
gptkb:133_S._Ct._1761 |
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
Association for Molecular Pathology v. Myriad Genetics, Inc.
|